[Form 4] Beam Therapeutics Inc. Insider Trading Activity

Rhea-AI Filing Summary

FMR LLC and related parties reported a disposition of Beam Therapeutics (BEAM) common stock. On 10/06/2025 the filing shows a disposal of 1,232,434 shares (transaction code G), leaving 841,231 shares beneficially owned following the transaction. The report lists additional indirect holdings: 1,139,443 shares held indirectly and 473 shares held by F-Prime Capital Partners Healthcare Fund V LP.

Remarks clarify that Abigail P. Johnson is a director, chair and CEO of FMR LLC and that members of the Johnson family collectively control 49% of FMR LLC voting power through Series B shares and a shareholders' voting agreement. The filing was signed on behalf of FMR LLC and affiliates by Stephanie J. Brown on 10/08/2025.

Positive

• Retains substantial indirect ownership of 1,139,443 shares
• Filing includes explanatory ownership remarks clarifying voting/control relationships

Negative

• Large disposition reported: 1,232,434 shares disposed on 10/06/2025
• Direct beneficial holdings reduced to 841,231 shares after the transaction

Insights

Corporate Governance / Insider Holdings Analyst

Insider group reported a large share disposition while retaining substantial indirect holdings.

The filing documents a 1,232,434-share disposal on 10/06/2025 under code G, which commonly denotes a gift or transfer not involving a cash sale. After the transaction, the reporting group retains 841,231 shares directly or indirectly, plus additional indirect holdings of 1,139,443 shares and a small fund position of 473 shares.

The remarks explain control relationships: Abigail P. Johnson and family members hold collective voting power of 49% in FMR LLC through Series B shares and a voting agreement, which explains why several entities file together. Monitor subsequent Section 16 filings for any further scheduled transfers or clarifying remarks within the next quarter.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FMR LLC

(Last) (First) (Middle)

245 SUMMER STREET

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remark 1

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								1,139,443	I	F-Prime Capital Partners Healthcare Fund V LP
Common Stock								473	I	FMR Capital, Inc.
Common Stock	10/06/2025		G		1,232,434	D	$0.00	841,231	I	Shares held by persons and entities whose shares are subject to reporting by the undersigned.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund V LP is F-Prime Capital Partners Healthcare Advisors Fund V LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. FMR Capital, Inc. is a wholly owned subsidiary of FMR LLC.

	/s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson	10/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 filing for BEAM report?

The filing reports a disposition of 1,232,434 BEAM shares on 10/06/2025, leaving 841,231 shares beneficially owned by the reporting group.

Who filed the Form 4 for BEAM and who is affected?

The Form 4 was filed by FMR LLC on behalf of itself and related entities, referencing Abigail P. Johnson and affiliated entities as reporting persons.

What does transaction code G mean on this Form 4?

Transaction code G is used in the filing; it commonly indicates a gift or similar transfer. The form does not state cash proceeds or sale price.

How much voting control does the Johnson family have at FMR LLC?

Remarks state the Johnson family collectively represent 49% of FMR LLC's voting power through Series B voting common shares and a shareholders' voting agreement.

Were any derivative securities reported in this Form 4 for BEAM?

No derivative securities are reported in Table II; the filing only lists common stock dispositions and indirect holdings.